Resistenza all’uso degli ipoglicemizzanti orali nel trattamento del diabete tipo 2: uno studio multicentrico

Resistenza all’uso degli ipoglicemizzanti orali nel trattamento del diabete tipo 2: uno studio multicentrico

Authors

  • Gianluca Falcitelli Consulente statistico, via G. Barzellotti 8, Roma 

  • Giuseppe Armentano Specialista in Diabetologia e Malattie del Ricambio, Direttore centro Diabetologico DEA di Rossano (CS) 

  • Corrado Pugliesi Ambulatorio di Diabetologia, Avola 

  • Patrizio Tatti U.O.C.Aziendale, AUSL Roma H, Roma 

  • Antonio Cimino Dirigente Medico, UO di Diabetologia, Spedali Civili di Brescia



DOI:

https://doi.org/10.7175/fe.v7i2.682

Keywords:

Type 2 diabetes, oral anti-diabetics, Insuline, Epidemiology, HbA1c

Abstract

Type 2 diabetes is an important social and health care system variable due to its large diffusion, frequency of clinical complications and its health care costs. The studied population is relative to 4 italian centers distributed all over the country (Brescia, Roma, Rossano Calabro and Avola). This work has the aim to describe the Italian type 2 population according to treatment choice ruled by diabetes stage, glycemia control and HbA1c concentration. The analysis present a description of the therapeutic changes during the year of observation too, giving a complete picture of patients distribution and their treatment path through diabetes evolution in Italy.

Downloads

Published

2006-09-15

How to Cite

Falcitelli, . G., Armentano, . G., Pugliesi, . C., Tatti, . P., & Cimino, . A. (2006). Resistenza all’uso degli ipoglicemizzanti orali nel trattamento del diabete tipo 2: uno studio multicentrico. Farmeconomia. Health Economics and Therapeutic Pathways, 7(2), 125–134. https://doi.org/10.7175/fe.v7i2.682

Issue

Section

Original research

Similar Articles

<< < 1 2 3 4 5 6 7 8 9 10 > >> 

You may also start an advanced similarity search for this article.

Loading...